Abstract
Anaplastic thyroid carcinoma is the most aggressive type of thyroid malignancies. Previously, we demonstrated that tumorigenicity of anaplastic thyroid carcinoma cell line ARO was significantly reduced following interleukin (IL)-12 gene transfer. We suspected that tumor target structure in ARO/IL-12 cells might be changed and such a change may make them more susceptible to be killed through mechanisms apart from natural killer-dependent pathway. To identify genes involved, we examined gene expression profile of ARO and ARO/IL-12 by microarray analysis of 3757 genes. The most highly expressed gene was cannabinoid receptor 2 (CB2), which was expressed eightfold higher in ARO/IL-12 cells than ARO cells. CB2 agonist JWH133 and mixed CB1/CB2 agonist WIN-55,212–2 could induce significantly higher rate of apoptosis in ARO/IL-12 than ARO cells. Similar results were obtained when ARO cells were transfected with CB2 transgene (ARO/CB2). A considerable regression of thyroid tumors generated by inoculation of ARO/CB2 cells was observed in nude mice following local administration of JWH133. We also demonstrated significant increase in the induction of apoptosis in ARO/IL12 and ARO/CB2 cells following incubation with 15 nM paclitaxel, indicating that tumor cells were sensitized to chemotherapy. These data suggest that CB2 overexpression may contribute to the regression of human anaplastic thyroid tumor in nude mice following IL-12 gene transfer. Given that cannabinoids have shown antitumor effects in many types of cancer models, CB2 may be a viable therapeutic target for the treatment of anaplastic thyroid carcinoma.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism
Cell Death & Disease Open Access 28 April 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout




References
Hundahl SA, Fleming ID, Fremgen AM, Menck HR . A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the US 1985–1995 [see comments]. Cancer 1998; 83: 2638–2648.
Farid NR, Shi Y, Zou M . Molecular basis of thyroid cancer. Endocr Rev 1994; 15: 202–232.
Are C, Shaha AR . Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13: 453–464.
Schott M, Scherbaum WA . Immunotherapy and gene therapy of thyroid cancer. Minerva Endocrinol 2004; 29: 175–187.
Barzon L, Pacenti M, Boscaro M, Palu G . Gene therapy for thyroid cancer. Expert Opin Biol Ther 2004; 4: 1225–1239.
Nanni P, Forni G, Lollini PL . Cytokine gene therapy: hopes and pitfalls. Ann Oncol 1999; 10: 261–266.
Wysocki PJ, Karczewska-Dzionk A, Mackiewicz-Wysocka M, Mackiewicz A . Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther 2004; 4: 1595–1607.
Sangro B, Melero I, Qian C, Prieto J . Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573–581.
Shi Y, Parhar RS, Zou M, Baitei E, Kessie G, Farid NR et al. Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein. Hum Gene Ther 2003; 14: 1741–1751.
Zou M, Famulski KS, Parhar RS, Baitei E, Al-Mohanna FA, Farid NR et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 2004; 89: 6146–6154.
Shi Y, Zou M, Collison K, Baitei EY, Al-Makhalafi Z, Farid NR et al. Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 2006; 91: 2373–2379.
Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61: 5784–5789.
Airoldi I, Di Carlo E, Banelli B, Moserle L, Cocco C, Pezzolo A et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 2004; 113: 1651–1659.
Herrera B, Carracedo A, Diez-Zaera M, Gomez del Pulgar T, Guzman M, Velasco G . The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res 2006; 312: 2121–2131.
Herrera B, Carracedo A, Diez-Zaera M, Guzman M, Velasco G . p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett 2005; 579: 5084–5088.
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20: 147–155.
Guzman M . Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3: 745–755.
Bifulco M, Laezza C, Pisanti S, Gazzerro P . Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 2006; 148: 123–135.
Bifulco M, Di Marzo V . Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002; 8: 547–550.
Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M . Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004; 64: 5617–5623.
Vasko VV, Saji M . Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol 2007; 19: 11–17.
Xing M . BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245–262.
Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 2005; 105: 1214–1221.
Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111: 43–50.
Sarfaraz S, Afaq F, Adhami VM, Mukhtar H . Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005; 65: 1635–1641.
Blazquez C, Carracedo A, Barrado L, Real PJ, Fernandez-Luna JL, Velasco G et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006; 20: 2633–2635.
Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006; 66: 6748–6755.
McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002; 100: 627–634.
Aguado T, Carracedo A, Julien B, Velasco G, Milman G, Mechoulam R et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem 2007; 282: 6854–6862.
Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006; 171: 31–38.
Acknowledgements
This research project was supported by a grant from King Abdulaziz City for Science and Technology (ARP-24-11). We thank Dr Raafat M El-Sayed from Animal Facility for his excellent support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shi, Y., Zou, M., Baitei, E. et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther 15, 101–107 (2008). https://doi.org/10.1038/sj.cgt.7701101
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7701101
Keywords
- interleukin-12
- gene therapy
- anaplastic thyroid carcinoma
- cannabinoid
- CB2 receptor
This article is cited by
-
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism
Cell Death & Disease (2011)
-
Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs
Clinical & Experimental Metastasis (2010)